In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.
|Articles|April 19, 2004
New antidepressant offers substantial savings
Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.
Advertisement
Advertisement
Related to this article
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
Advertisement
Advertisement